Clinical trials: Genomic Testing
Gynecologic Cancer
Molecular Data and Their Correlations With Clinical Outcomes in Gynecological Cancer Patients.
Gynger is a no profit, observational study, composed of a retrospective cohort (A) and a prospective cohort (B). The primary aim of this trial is to describe gene profile of Italian gynecological cancers patients, through the…
- Trial name
- GYNGER (NCT05733793)
- Testing
- NGS tests
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- National Cancer Institute, Naples
Muscle Invasive Bladder Cancer
Clinical Performance Evaluation of the C2i Test
The overall objective of this study is to demonstrate the safety and effectiveness by means of investigation of the ability of C2i-Test to predict 2-year recurrence-free survival post-RC in stage II-IIIA MIBC patients.
- Trial name
- NCT05860543
- Testing
- C2i-WGS-MRD Test
- Sponsor
- University of Texas Southwestern Medical Center
Adenocarcinoma of Lung
Comparative Genomic Profiling of Lung Adenocarcinoma in Asians and Caucasians: A Propensity Matched Analysis
Lung adenocarcinomas (LUADs) from Asian ancestry are reported to have different genomic architectures compared with LUADs from Caucasian ancestry.
- Trial name
- NCT04692935
- Volunteers
- 450 people
- Sponsor
- Jun Wang
Solid Tumors, Hematological Malignancies
Molecular Testing of Cancer by Integrated Genomic, Transcriptomic, and Proteomic Analysis
The purpose of this study is to discover genetic changes associated with different cancers. With the information from this study the investigators hope to provide better ways to prevent, detect and treat many cancers.
- Trial name
- NCT02213822
- Testing
- Molecular Analysis of Cancer
- Where
- 3 sites in United States
- Volunteers
- 500 people
- Sponsor
- Rhode Island Hospital
Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia
Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Functional precision medicine (FPM) is a relatively new approach to cancer therapy based on direct exposure of patient- isolated tumor cells to clinically approved drugs and integrates ex vivo drug sensitivity testing (DST) and…
- Conditions
- Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Large Cell Lymphoma, Refractory Childhood Acute Lymphoblastic Leukemia
- Trial name
- NCT05857969
- Testing
- Functional Precision Medicine
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Florida International University
Prostate Cancer
Registry to Measure the Impact of Adding Genomic Testing
This is a prospective open registry to measure the impact on first-line therapy of genomic testing of biopsy tissue from recently diagnosed treatment-naïve patients with early stage localized prostate cancer.
- Trial name
- NCT02454595
- Testing
- Registry
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- Myriad Genetic Laboratories, Inc.
Colon Cancer
A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint
The aim of this study is to enroll 785 eligible stage II colon cancer patients in order to validate the performance of ColoPrint in estimating 3-year relapse rate.
- Trial name
- PARSC (NCT00903565)
- Where
- 35 sites in United States, Austria and 10 more
- Volunteers
- 1,200 people
- Sponsor
- Agendia
Eczema/Atopic Dermatitis, Cancer
Patient Forward Access to Clinical and Technological Research: Genetic Influences on Cancer and Atopic Dermatitis
This Patient Forward study intends to conduct research to investigate potential genetic factors causing cancer and eczema/atopic dermatitis.
- Trial name
- PFACTR02 (NCT04362852)
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Boston Children's Hospital
Psoriasis
Genomic Study for the Prediction of Efficacy and Adverse Effects of CD11a Monoclonal Antibodies(Raptiva)
The pathogenesis of psoriasis has evolved from epidermal hyperproliferation to immune dysregulation in recent years. A Th1 cytokine profile is universally found is psoriasis.
- Trial name
- NCT00602823
- Volunteers
- 20 people
- Sponsor
- National Taiwan University Hospital
Metastatic Breast Cancer
Patient-Centric Study to Assess the Impact of Genomic Profiling on the Treatment of Patients With Metastatic Breast Cancer in Spain
HOPE Focus is an observational study that aims at promoting research against metastatic breast cancer by means of collective research led by patients (patient-centric trial).
- Trial name
- HOPE-Focus (NCT06991946)
- Testing
- Liquid Biopsy, Archival Tumor DNA
- Where
- Spain
- Volunteers
- 300 people
- Sponsor
- SOLTI Breast Cancer Research Group
Genetic Screening, Adolescent
Engaging Adolescents in Decisions About Return of Genomic Research Results
Recent recommendations to return children's results for adult-onset conditions to parents anytime whole exome or genome sequencing is performed, as well as growing expectations to return research results to participants on a…
- Conditions
- Genetic Screening, Adolescent, Genetic Change, Shared Decision Making
- Trial name
- NCT04481061
- Testing
- Electronic Decision Tool
- Where
- 2 sites in United States
- Volunteers
- 787 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Coronary Artery Disease, Proteus Syndrome
Informed Consent for Whole Genome Sequencing: Ideals and Norms Referenced by Early Participants
Since 2007, the cost of sequencing a diploid human genome has fallen dramatically, from approximately $70 million to $20,000. As affordable sequencing platforms become more widely available, the advancement of biomedical science…
- Conditions
- Coronary Artery Disease, Proteus Syndrome, Coffin - Sins Syndrome, Familial Isolated Hyperparathyroidism
- Trial name
- NCT01369953
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Thyroid Nodule, Thyroid Cancer
Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer
The purpose of this registry is to collect uniform genomics-centered data on patients with nodular thyroid disease and cancer in a prospective fashion.
- Conditions
- Thyroid Nodule, Thyroid Cancer, Thyroid Diseases, Thymic Carcinoma
- Trial name
- NCT03170804
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Aventura Hospital and Medical Center
Early-Stage Breast Cancer, Neoadjuvant Therapy
COGNITION: Genomics-Guided Precision Oncology in Early High-Risk Breast Cancer
The COGNITION diagnostic platform elucidates the biomarker profile of neoadjuvant chemotherapy-resistant residual bulk tumors in high risk early breast cancer patients.
- Trial name
- COGNITION (NCT05906407)
- Testing
- Genomic Profiling / Sequencing
- Where
- 12 sites in Germany
- Volunteers
- 2,000 people
- Sponsor
- German Cancer Research Center
Advanced Lymphoma, Refractory Lymphoma
Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies
EXALT-2 is a prospective, randomized, three arm study for treatment decision guided either by either comprehensive genomic profiling, next generation drug screening or physician's choice
- Conditions
- Advanced Lymphoma, Refractory Lymphoma, Refractory Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- EXALT-2 (NCT04470947)
- Testing
- Next generation functional drug screening, Comprehensive genomic profiling
- Where
- Austria
- Volunteers
- 150 people
- Sponsor
- Medical University of Vienna
Breast Cancer
Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients
This multicenter, prospectively designed study examines whether the Prosigna score influences physician and patient adjuvant treatment selection over and above currently used prognostic factors.
- Trial name
- NCT02625935
- Where
- 4 sites in United States
- Volunteers
- 206 people
- Sponsor
- NanoString Technologies, Inc.
Whole Genome Sequencing, Myelodysplastic Syndromes
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDS
This is a single institution, prospective study of the whole genome sequencing assay, ChromoSeq. Using prospectively collected patient data, coupled with physician surveys, the investigators seek to determine the feasibility of…
- Trial name
- NCT05434598
- Testing
- ChromoSeq
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Epithelial Ovarian Cancer, Peritoneal Cancer
Genomic BRCA and Extensive ovArian Cancer Testing
This is a prospective observational French multicenter cohort in patients with ovarian and/or primitive peritoneal and/or fallopian tubes carcinoma, histologically confirmed, with an advanced stage at diagnosis (stage III to IV…
- Conditions
- Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- GREAT (NCT04027868)
- Where
- 137 sites in France
- Volunteers
- 1,500 people
- Sponsor
- ARCAGY/ GINECO GROUP
Bladder Cancer, Urine Marking
Genomic Imprinting Testing for Diagnosis of Bladder Cancer
Urine analysis provide a promising non-invasive liquid biopsy for diagnosis of bladder cancer. Molecular biomarkers in urine may serve as important diagnostic and prognostic indicators for bladder cancer.
- Conditions
- Bladder Cancer, Urine Marking, Diagnoses Disease
- Trial name
- NCT03563443
- Testing
- Genomic Imprinting Testing
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Changhai Hospital
Neoplasms, Unknown Primary, CUP
Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary
The goal of the current study is to determine whether Foundation Medicine's next generation sequencing assay, called FoundationOne, will provide information that allows physicians to make treatment decisions using targeted…
- Conditions
- Neoplasms, Unknown Primary, CUP, Metastatic Disease, Poorly Differentiated Adenocarcinoma
- Trial name
- NCT02628379
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Foundation Medicine